Clinical Trial Update: Alimta and Gemcitabine in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Alimta (pemetrexed) and gemcitabine in patients with non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Southern Italy Cooperative Oncology Group | Conditions: Non-Small Cell Lung Cancer, Stage IIIB or IV | Phase 2 | Status: COMPLETED